解放军医学院学报2015，Vol.36Issue(6)：590-594,5.DOI:10.3969/j.issn.2095-5227.2015.06.019
西妥昔单抗联合化疗一线治疗K-RAS野生型晚期结直肠癌疗效观察
Efficacy observation of cetuximab combined with chemotherapy for patients with K-RAS wild-type advanced colorectal cancer
李娟 1张婷婷 1王以尚 1韩春 1白莉1
作者信息
- 1. 解放军总医院 肿瘤内一科,北京 100853
- 折叠
摘要
Abstract
ObjectiveTo investigate the efficacy and safety of cetuximab with FOLFIRI or FOLFOX/XELOX as first-line chemotherapy for patients with K-RAS wild-type advanced colorectal cancer.MethodsClinical data about 98 histopathology confirmed patients with KRAS wild-type advanced colorectal cancer admitted to our hospital from February 2008 to July 2014 were collected and analyzed. Forty-four patients received cetuximab plus FOLFOX/XELOX, 54 patients received cetuximab plus FOLFIRI. Each patient received at least two cycles of chemotherapy, every 6 weeks for evaluation. The efficacy was evaluated according to RECIST 1.1.ResultsNinety-eight patients were available for evaluation. In cetuximab plus FOLFOX/XELOX group, the complete response (CR) was 2.27%, partial response (PR) was 63.64%, stable disease (SD) was 25%, and progressive disease (PD) was 9.09%. In cetuximab plus FOLFIRI group, CR was 0%, PR was 40.74%, SD was 44.45%, PD was 14.81%. The objective response rate (ORR) of these two groups were 65.91% and 40.74%, respectively, which was of statistically significant difference (P=0.013). The disease control rate (DCR) were 90.91% and 85.19% respectively, which showed statisticallysignificant difference (P=0.390). The median progression-free survival (PFS) was 8.4 months and 7.7 months respectively, with no statistically significant differences (P=0.580).ConclusionThe efficacy of addition of cetuximab to oxaliplatin-based chemotherapy infirst-line treatment for K-RAS wild-type advanced colorectal cancer is not inferior to cetuximab combined with FOLFIRI regimen. Adverse reactions show no significant difference between the two groups, which suggests that it is worthy of promotion.关键词
结直肠肿瘤/西妥昔单抗/化学治疗Key words
colorectal neoplasms/cetuximab/chemotherapy分类
医药卫生引用本文复制引用
李娟,张婷婷,王以尚,韩春,白莉..西妥昔单抗联合化疗一线治疗K-RAS野生型晚期结直肠癌疗效观察[J].解放军医学院学报,2015,36(6):590-594,5.
